ReviewCureus2025
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Myeloid Leukemia: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of HLA-B leader matching on clinical outcomes of haploidentical hematopoietic stem cell transplantation in adult patients with acute leukemia, a retrospective cohort study.Annals of medicine and surgery (2012) · 2026Article
- Acute Myeloid Leukemia Survivors Report Transplant-specific Burdens in Interviews Two Years after Receiving Allogeneic Hematopoietic Cell Transplantation During the Peak of the COVID-19 Pandemic: A Qualitative Study.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for adult acute myeloid leukemia (AML), but its outcomes are influenced by donor selection, conditioning regimens, and patient-specific factors. This systematic review synthesizes recent evidence on survival, relapse, non-relapse mortality (NRM), and prognostic factors to guide clinical decision-making. A comprehensive search of PubMed, Scopus, Web of Science, Embase, and ClinicalTrials.gov (January 2020-August 2025) identified 10 studies meeting the inclusion criteria. Studies were evaluated for outcomes (overall survival (OS), disease-free survival (DFS), relapse, and NRM) and risk of bias using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk of Bias (RoB) 2 tool. Haploidentical HSCT improved one-year survival (77.9% vs. 62.0% with chemotherapy) in elderly AML, with lower relapse (16.5% vs. 56.6%). Matched sibling donors (MSD) yielded superior two-year OS (62.4%) compared to unrelated/haploidentical donors, though relapse rates were comparable. Reduced-intensity conditioning (RIC) increased NRM in patients ≥70 years, while nonmyeloablative regimens improved tolerability. Transplantation in complete remission (CR) was critical (five-year OS: 58% vs. 6% for non-CR). Autologous HSCT outperformed allo-HSCT in acute promyelocytic leukemia (APL) complete remission 2 (CR2) (82.4% vs. 64.3% two-year OS). Allo-HSCT benefits intermediate/poor-risk AML, with MSD and CR transplantation offering optimal outcomes. Haploidentical HSCT is viable for older patients lacking matched donors. Future research should prioritize prospective trials to refine donor selection and conditioning strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.